Medicenna Therapeutics presents new preclinical data from MDNA113

Medicenna Therapeutics (MDNAF) presented new positive preclinical data from MDNA113, its first-in-class tumor-anchored and conditionally activated anti-PD-1 x IL-2 bifunctional Superkine, at the American Association for Cancer Research Annual Meeting 2026 in San Diego, California. The data demonstrate that MDNA113’s architecture “delivers on the promise of a truly differentiated and highly tolerable PD-1 x IL-2 bifunctional,” the company said. In a head-to-head non-human primate study, MDNA113 was well tolerated at doses up to 50 mg/kg while a representative anti-PD-1 x IL-2alpha-biased bispecific could not be administered a second dose at a fraction of that exposure due to severe toxicity, including evidence of vascular leak syndrome. MDNA113 is built on the Company’s IL-2 and IL-13 Superkine platforms. MDNA113 is designed to address the safety and dosing limitations that have constrained first-generation molecules in this class by combining a commercially validated anti-PD-1 antibody with Medicenna’s clinically validated IL-2 Superkine, the only next-generation IL-2 with demonstrated durable single-agent anti-tumor activity, in a tumor-targeted, conditionally activated architecture.